Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

We believe that pharmacologic innovation is needed in treating patients with cardiogenic shock,” said Dr. Steve Simonson, CMO and SVP of Windtree. “Currently available drugs can have unwanted ...

We believe that pharmacologic innovation is needed in treating patients with cardiogenic shock,” said Dr. Steve Simonson, CMO and SVP of Windtree. "Currently available drugs can have unwanted side ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

SCAI Stage C cardiogenic shock is characterized by significant organ hypoperfusion, necessitating the use of inotropic or ...

KL4 Surfactant is under clinical development by Windtree Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

[Impact of VA-ECMO combined with IABP and timing on outcome of patients with acute myocardial infarction complicated with cardiogenic shock]. [Predictive value of low-density lipoprotein ...